RxDoctor Payments Data

Jianfeng Wang, MD

Internal Medicine · Cambridge, MANPI 1922395664

Payments from drug & device makers

$20,643in general payments, 2019–2025

Across 78 payments — averaging $264.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$19K
  • Novartis$242
  • Gilead$165
  • Pharmacyclics LLC, An Abbvie Company$141
  • Incyte Corporation$135
  • Pfizer$124
  • plus $641 from 16 others

What the payments were for

  • Food & beverage$1,28782%
  • Education$28018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$20,643 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$125,426
Medicare patients
460
Services billed
1,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide48$672,182
VenclextaVenetoclax74$651,409
PomalystPomalidomide25$624,503
Lenalidomide44$502,042
JakafiRuxolitinib Phosphate22$324,050
KisqaliRibociclib Succinate19$276,831
IbrancePalbociclib13$210,407
BrukinsaZanubrutinib13$194,690
ErleadaApalutamide13$189,139
LynparzaOlaparib11$179,285
EliquisApixaban165$120,827
InqoviDecitabine/Cedazuridine14$115,863
NeupogenFilgrastim24$66,965
Abiraterone Acetate38$63,190
XareltoRivaroxaban24$22,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$73$672,18248 claims
AbbVieVenclexta$84$651,40974 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$19,196$624,50325 claims
PfizerIbrance, Eliquis$124$331,233178 claims
Incyte CorporationJakafi$135$324,05022 claims
NovartisKisqali$242$276,83119 claims
Johnson & JohnsonErleada, Xarelto$21$211,45037 claims
AstraZenecaLynparza$68$179,28511 claims
AmgenNeupogen$104$66,96524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Cambridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →